Search

Your search keyword '"Pipitone, Stefania"' showing total 31 results
Start Over Author "Pipitone, Stefania"
31 results on '"Pipitone, Stefania"'

1. Long-term responders to nivolumab in previously treated advanced renal cell carcinoma: a sub-analysis of meet-URO15 study

Author

Messina, Carlo, Catalano, Martina, Roviello, Giandomenico, Gandini, Annalice, Maruzzo, Marco, De Giorgi, Ugo, Pedrazzoli, Paolo, Sbrana, Andrea, Zucal, Paolo Andrea, Masini, Cristina, Naglieri, Emanuele, Procopio, Giuseppe, Milella, Michele, Catalano, Fabio, Fratino, Lucia, Pipitone, Stefania, Ricotta, Riccardo, Panni, Stefano, Mollica, Veronica, Soraru, Mariella, Prati, Veronica, Atzori, Francesco, Di Napoli, Marilena, Messina, Marco, Morelli, Franco, Prati, Giuseppe, Nole, Franco, Malgeri, Andrea, Tudini, Marianna, Vignani, Francesca, Cavo, Alessia, Signori, Alessio, Banna, Giuseppe Luigi, Rescigno, Pasquale, Buti, Sebastiano, Rebuzzi, Sara Elena, and Fornarini, Giuseppe

Published
2024
Full Text
View/download PDF

2. Avelumab Plus Intermittent Axitinib in Previously Untreated Patients with Metastatic Renal Cell Carcinoma. The Tide-A Phase 2 Study

Author

Iacovelli, Roberto, Ciccarese, Chiara, Buti, Sebastiano, Zucali, Paolo Andrea, Fantinel, Emanuela, Bimbatti, Davide, Verzoni, Elena, Accettura, Caterina, Bonomi, Lucia, Buttigliero, Consuelo, Fornarini, Giuseppe, Pipitone, Stefania, Atzori, Francesco, Masini, Cristina, Massari, Francesco, Primi, Francesca, Strusi, Alessandro, Giudice, Giulia Claire, Perrino, Matteo, Maruzzo, Marco, Milella, Michele, Giannarelli, Diana, Brunelli, Matteo, Procopio, Giuseppe, and Tortora, Giampaolo

Published
2024
Full Text
View/download PDF

4. Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours

Author

Celsa, Ciro, Cabibbo, Giuseppe, Fulgenzi, Claudia A.M., Scheiner, Bernhard, D’Alessio, Antonio, Manfredi, Giulia F., Nishida, Naoshi, Ang, Celina, Marron, Thomas U., Saeed, Anwaar, Wietharn, Brooke, Pinter, Matthias, Cheon, Jaekyung, Huang, Yi-Hsiang, Lee, Pei-Chang, Phen, Samuel, Gampa, Anuhya, Pillai, Anjana, Vivaldi, Caterina, Salani, Francesca, Masi, Gianluca, Roehlen, Natascha, Thimme, Robert, Vogel, Arndt, Schönlein, Martin, von Felden, Johann, Schulze, Kornelius, Wege, Henning, Galle, Peter R., Kudo, Masatoshi, Rimassa, Lorenza, Singal, Amit G., El Tomb, Paul, Ulahannan, Susanna, Parisi, Alessandro, Chon, Hong Jae, Hsu, Wei-Fan, Stefanini, Bernardo, Verzoni, Elena, Giusti, Raffaele, Veccia, Antonello, Catino, Annamaria, Aprile, Giuseppe, Guglielmini, Pamela Francesca, Di Napoli, Marilena, Ermacora, Paola, Antonuzzo, Lorenzo, Rossi, Ernesto, Verderame, Francesco, Zustovich, Fable, Ficorella, Corrado, Di Pietro, Francesca Romana, Battelli, Nicola, Negrini, Giorgia, Grossi, Francesco, Bordonaro, Roberto, Pipitone, Stefania, Banzi, Maria, Ricciardi, Serena, Laera, Letizia, Russo, Antonio, De Giorgi, Ugo, Cavanna, Luigi, Sorarù, Mariella, Montesarchio, Vincenzo, Bordi, Paola, Brunetti, Leonardo, Pinto, Carmine, Bersanelli, Melissa, Cammà, Calogero, Cortellini, Alessio, and Pinato, David J.

Published
2024
Full Text
View/download PDF

5. Cerebellar metastasis of ovarian cancer: a case report

Author

Cabitza, Eleonora, Pirola, Marta, Baldessari, Cinzia, Bernardelli, Giuditta, Zunarelli, Elena, Pipitone, Stefania, Vitale, Maria Giuseppa, Nasso, Cecilia, Molinaro, Eleonora, Oltrecolli, Marco, D’Agostino, Elisa, Mandato, Vincenzo Dario, Palicelli, Andrea, Dominici, Massimo, and Sabbatini, Roberto

Published
2023
Full Text
View/download PDF

6. Using peripheral immune-inflammatory blood markers in tumors treated with immune checkpoint inhibitors: An INVIDIa-2 study sub-analysis

Author

Anpalakhan, Shobana, Signori, Alessio, Cortellini, Alessio, Verzoni, Elena, Giusti, Raffaele, Aprile, Giuseppe, Ermacora, Paola, Catino, Annamaria, Pipitone, Stefania, Di Napoli, Marilena, Scotti, Vieri, Mazzoni, Francesca, Guglielmini, Pamela F., Veccia, Antonello, Maruzzo, Marco, Schinzari, Giovanni, Casadei, Chiara, Grossi, Francesco, Rizzo, Mimma, Montesarchio, Vincenzo, Verderame, Francesco, Mencoboni, Manlio, Zustovich, Fable, Fratino, Lucia, Accettura, Caterina, Cinieri, Saverio, Tondini, Carlo Alberto, Camerini, Andrea, Banzi, Maria Chiara, Sorarù, Mariella, Zucali, Paolo Andrea, Vignani, Francesca, Ricciardi, Serena, Russo, Antonio, Cosenza, Agnese, Di Maio, Massimo, De Giorgi, Ugo, Pignata, Sandro, Giannarelli, Diana, Pinto, Carmine, Buti, Sebastiano, Fornarini, Giuseppe, Rebuzzi, Sara Elena, Rescigno, Pasquale, Addeo, Alfredo, Banna, Giuseppe L., and Bersanelli, Melissa

Published
2023
Full Text
View/download PDF

7. The prognostic value of the previous nephrectomy in pretreated metastatic renal cell carcinoma receiving immunotherapy: a sub-analysis of the Meet-URO 15 study

Author

Rebuzzi, Sara Elena, Signori, Alessio, Banna, Giuseppe Luigi, Gandini, Annalice, Fornarini, Giuseppe, Damassi, Alessandra, Maruzzo, Marco, De Giorgi, Ugo, Basso, Umberto, Chiellino, Silvia, Galli, Luca, Zucali, Paolo Andrea, Fantinel, Emanuela, Naglieri, Emanuele, Procopio, Giuseppe, Milella, Michele, Boccardo, Francesco, Fratino, Lucia, Pipitone, Stefania, Ricotta, Riccardo, Panni, Stefano, Mollica, Veronica, Sorarù, Mariella, Santoni, Matteo, Cortellini, Alessio, Prati, Veronica, Soto Parra, Hector Josè, Santini, Daniele, Atzori, Francesco, Di Napoli, Marilena, Caffo, Orazio, Messina, Marco, Morelli, Franco, Prati, Giuseppe, Nolè, Franco, Vignani, Francesca, Cavo, Alessia, Roviello, Giandomenico, Rescigno, Pasquale, and Buti, Sebastiano

Published
2022
Full Text
View/download PDF

8. New Advances in Metastatic Urothelial Cancer: A Narrative Review on Recent Developments and Future Perspectives.

Author

Tonni, Elena, Oltrecolli, Marco, Pirola, Marta, Tchawa, Cyrielle, Roccabruna, Sara, D'Agostino, Elisa, Matranga, Rossana, Piombino, Claudia, Pipitone, Stefania, Baldessari, Cinzia, Bacchelli, Francesca, Dominici, Massimo, Sabbatini, Roberto, and Vitale, Maria Giuseppa

Subjects
FIBROBLAST growth factor receptors, IMMUNE checkpoint inhibitors, TRANSITIONAL cell carcinoma, METASTASIS, CANCER chemotherapy
Abstract

The standard of care for advanced or metastatic urothelial carcinoma (mUC) was historically identified with platinum-based chemotherapy. Thanks to the advances in biological and genetic knowledge and technologies, new therapeutic agents have emerged in this setting recently: the immune checkpoint inhibitors and the fibroblast growth factor receptor inhibitors as the target therapy for patients harboring alterations in the fibroblast growth factor receptor (FGFR) pathway. However, chasing a tumor's tendency to recur and progress, a new class of agents has more recently entered the scene, with promising results. Antibody–drug conjugates (ADCs) are in fact the latest addition, with enfortumab vedotin being the first to receive accelerated approval by the U.S. Food and Drug Administration in December 2019, followed by sacituzumab govitecan. Many other ADCs are still under investigation. ADCs undoubtedly represent the new frontier, with the potential of transforming the management of mUC treatment in the future. Therefore, we reviewed the landscape of mUC treatment options, giving an insight into the molecular basis and mechanisms, and evaluating new therapeutic strategies in the perspective of more and more personalized treatments. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

9. Sodium levels and immunotherapy efficacy in mRCC patients with bone metastases: sub analysis of Meet-Uro 15 study.

Author

Catalano, Martina, Rebuzzi, Sara Elena, Maruzzo, Marco, De Giorgi, Ugo, Buti, Sebastiano, Galli, Luca, Fornarini, Giuseppe, Zucali, Paolo Andrea, Claps, Melanie, Chiellino, Silvia, Zampiva, Ilaria, Pipitone, Stefania, Ricotta, Riccardo, Sorarù, Mariella, Mollica, Veronica, Tudini, Marianna, Fratino, Lucia, Prati, Veronica, Caffo, Orazio, and Atzori, Francesco

Subjects
TREATMENT effectiveness, BONE metastasis, SODIUM, IMMUNE checkpoint inhibitors, RENAL cell carcinoma, HYPERNATREMIA
Abstract

Background: Immune-checkpoint inhibitors (ICIs) have significantly improved metastatic renal cell carcinoma (mRCC) prognosis, although their efficacy in patients with bone metastases (BMs) remains poorly understood. We investigated the prognostic role of natremia in pretreated RCC patients with BMs receiving immunotherapy. Materials and Methods: This retrospective multicenter study included RCC patients with BMs receiving nivolumab as second-line therapy or beyond. Inclusion criteria involved baseline sodium levels (pre-ICI) and sodium levels after 4 weeks of nivolumab initiation (post-ICI). The population was divided into two groups based on the median value, and response rates, progression-free survival (PFS), and overall survival (OS) were assessed. Results: Among 120 eligible patients, those with pre-treatment sodium levels =140 mEq/L showed longer OS (18.7 vs. 12.0 months, p=0.04). Pre-treatment sodium levels =140 mEq/L were associated with better OS compared to levels <140 mE/L (18.7 vs. 12.0, p=0.04). Post-treatment sodium levels =140mEq/L were associated with improved PFS (9.6 vs. 3.2 months) and OS (25.1 vs. 8.8 months) (p=0.05 and p<0.01, respectively). Patients with consistent sodium levels =140 mEq/L at both time points exhibited the best outcomes compared to those with lower values (PFS 11.5 vs. 3.3 months and OS 42.2 vs. 9.0 months, respectively, p<0.01). Disease control rate was significantly higher in the latter group (p<0.01). Multivariate analysis confirmed the prognostic significance of sodium levels. Conclusion: Elevated sodium levels (=140 mEq/L) pre- and post-ICI treatment correlate with better survival outcomes in mRCC patients with BMs. This finding suggests sodium level assessment as a potential prognostic factor in these patients and warrants further investigation, particularly in combination immunotherapy settings. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

10. Correlation Between Immune-related Adverse Event (IRAE) Occurrence and Clinical Outcome in Patients With Metastatic Renal Cell Carcinoma (mRCC) Treated With Nivolumab: IRAENE Trial, an Italian Multi-institutional Retrospective Study

Author

Vitale, Maria Giuseppa, Pipitone, Stefania, Venturelli, Marta, Baldessari, Cinzia, Porta, Camillo, Iannuzzi, Federica, Basso, Umberto, Scagliarini, Sarah, Zucali, Paolo Andrea, Galli, Luca, Rossetti, Sabrina, Caserta, Claudia, Bracarda, Sergio, Iacovelli, Roberto, Masini, Cristina, Cortellini, Alessio, Di Girolamo, Stefania, Buti, Sebastiano, Fornarini, Giuseppe, Carrozza, Francesco, Santoni, Matteo, Caputo, Francesco, Giaquinta, Stefania, Balduzzi, Sara, D’Amico, Roberto, Vitale, Giovanna, Mighali, Pasquale, and Sabbatini, Roberto

Published
2020
Full Text
View/download PDF

11. Long-term responders to nivolumab in previously treated advanced renal cell carcinoma: a sub-analysis of Meet-URO15 study

Author

Messina, Carlo, primary, Catalano, Martina, additional, roviello, giandomenico, additional, Gandini, Annalice, additional, Maruzzo, Marzo, additional, De Giorgi, Ugo, additional, Pedrazzoli, Paolo, additional, Sbrana, Andrea, additional, Zucali, Paolo Ansrea, additional, Masini, Cristina, additional, Naglieri, Emanuele, additional, Procopio, Giuseppe, additional, Milella, Michele, additional, Catalano, Fabio, additional, Fratino, Lucia, additional, Pipitone, Stefania, additional, Ricotta, Riccardo, additional, Panni, Stefano, additional, Mollica, Veronica, additional, Atzori, Francesco, additional, Napoli, Marilena Di, additional, Messina, Marco, additional, Morelli, Franco, additional, Prati, Giuseppe, additional, Nolè, Franco, additional, Malgeri, Andrea, additional, Tudini, Marianna, additional, Vignani, Francesca, additional, Cavo, Alessia, additional, Signori, Alessio, additional, Banna, Giuseppe Luigi, additional, Rescigno, Pasquale, additional, Buti, Stefano, additional, Rebuzzi, Sara Elena, additional, and Fornarini, Giuseppe, additional

Published
2024
Full Text
View/download PDF

12. Homologous Recombination Repair Deficiency in Metastatic Prostate Cancer: New Therapeutic Opportunities.

Author

Piombino, Claudia, Pipitone, Stefania, Tonni, Elena, Mastrodomenico, Luciana, Oltrecolli, Marco, Tchawa, Cyrielle, Matranga, Rossana, Roccabruna, Sara, D'Agostino, Elisa, Pirola, Marta, Bacchelli, Francesca, Baldessari, Cinzia, Baschieri, Maria Cristina, Dominici, Massimo, Sabbatini, Roberto, and Vitale, Maria Giuseppa

Subjects
*HOMOLOGOUS recombination, *DNA repair, *PROSTATE cancer, *METASTASIS, *ANDROGEN receptors, *CLINICAL trials, *LUTEINIZING hormone releasing hormone
Abstract

More than 20% of metastatic prostate cancer carries genomic defects involving DNA damage repair pathways, mainly in homologous recombination repair-related genes. The recent approval of olaparib has paved the way to precision medicine for the treatment of metastatic prostate cancer with PARP inhibitors in this subset of patients, especially in the case of BRCA1 or BRCA2 pathogenic/likely pathogenic variants. In face of this new therapeutic opportunity, many issues remain unsolved. This narrative review aims to describe the relationship between homologous recombination repair deficiency and prostate cancer, the techniques used to determine homologous recombination repair status in prostate cancer, the crosstalk between homologous recombination repair and the androgen receptor pathway, the current evidence on PARP inhibitors activity in metastatic prostate cancer also in homologous recombination repair-proficient tumors, as well as emerging mechanisms of resistance to PARP inhibitors. The possibility of combination therapies including a PARP inhibitor is an attractive option, and more robust data are awaited from ongoing phase II and phase III trials outlined in this manuscript. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

13. Sodium Levels and Outcomes in Patients With Metastatic Renal Cell Carcinoma Receiving Nivolumab

Author

Catalano, Martina, primary, Rebuzzi, Sara Elena, additional, Maruzzo, Marco, additional, De Giorgi, Ugo, additional, Buti, Sebastiano, additional, Galli, Luca, additional, Fornarini, Giuseppe, additional, Zucali, Paolo Andrea, additional, Procopio, Giuseppe, additional, Chiellino, Silvia, additional, Milella, Michele, additional, Catalano, Fabio, additional, Pipitone, Stefania, additional, Ricotta, Riccardo, additional, Sorarù, Mariella, additional, Mollica, Veronica, additional, Tudini, Marianna, additional, Fratino, Lucia, additional, Prati, Veronica, additional, Caffo, Orazio, additional, Atzori, Francesco, additional, Morelli, Franco, additional, Prati, Giuseppe, additional, Nolè, Franco, additional, Vignani, Francesca, additional, Cavo, Alessia, additional, Di Napoli, Marilena, additional, Malgeri, Andrea, additional, Naglieri, Emanuele, additional, Signori, Alessio, additional, Banna, Giuseppe Luigi, additional, Rescigno, Pasquale, additional, Antonuzzo, Lorenzo, additional, and Roviello, Giandomenico, additional

Published
2023
Full Text
View/download PDF

16. Pembrolizumab in Vaginal Carcinoma: A Case Report and Review of the Literature.

Author

Vitale, Maria Giuseppa, Nasso, Cecilia, Riccò, Beatrice, Bocconi, Alessandro, Chiavelli, Chiara, Baldessari, Cinzia, Pipitone, Stefania, Bacchelli, Francesca, Botticelli, Laura, Dominici, Massimo, and Sabbatini, Roberto

Subjects
LITERATURE reviews, VAGINAL cancer, PEMBROLIZUMAB, CARCINOMA, GOVERNMENT aid, VULVAR cancer, GYNECOLOGIC cancer
Abstract

Introduction: Vaginal cancer is a rare gynecologic malignancy. While in a localized disease, concurrent chemoradiation grants local control and better overall survival, in a metastatic setting, the management options are very limited. Furthermore, recurrent cervical, vulvar, and vaginal carcinomas notoriously develop resistance to treatment, and consequently, their prognosis is still poor. Case Presentation: We herein present the case of a woman with a nodal relapse of vaginal carcinoma, effectively treated with third-line immunotherapy. We will also provide a review of the literature on the new therapeutic strategies for advanced vaginal carcinoma, with a focus on pembrolizumab immunotherapy. Conclusion: Pembrolizumab might represent a promising option for the management of vaginal and vulvar cancer, but data to support its use in this setting are still lacking. This case highlights the need for further investigation and trial designs for this rare disease. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

17. Chasing the Role of miRNAs in RCC: From Free-Circulating to Extracellular-Vesicle-Derived Biomarkers

Author

Mastrolia, Ilenia, primary, Catani, Virginia, additional, Oltrecolli, Marco, additional, Pipitone, Stefania, additional, Vitale, Maria Giuseppa, additional, Masciale, Valentina, additional, Chiavelli, Chiara, additional, Bortolotti, Carlo Augusto, additional, Nasso, Cecilia, additional, Grisendi, Giulia, additional, Sabbatini, Roberto, additional, and Dominici, Massimo, additional

Published
2023
Full Text
View/download PDF

18. Chasing Circulating Biomarkers in Renal Cell Carcinoma: the Case of Extracellular Vesicles and their miRNA Cargos

Author

Mastrolia, Ilenia, primary, Catani, Virginia, additional, Oltrecolli, Marco, additional, Pipitone, Stefania, additional, Vitale, Maria Giuseppa, additional, Masciale, Valentina, additional, Chiavelli, Chiara, additional, Bortolotti, Carlo Augusto, additional, Nasso, Cecilia, additional, Grisendi, Giulia, additional, Sabbatini, Roberto, additional, and Dominici, Massimo, additional

Published
2023
Full Text
View/download PDF

19. Bone Metastases and Health in Prostate Cancer: From Pathophysiology to Clinical Implications

Author

Baldessari, Cinzia, primary, Pipitone, Stefania, additional, Molinaro, Eleonora, additional, Cerma, Krisida, additional, Fanelli, Martina, additional, Nasso, Cecilia, additional, Oltrecolli, Marco, additional, Pirola, Marta, additional, D’Agostino, Elisa, additional, Pugliese, Giuseppe, additional, Cerri, Sara, additional, Vitale, Maria Giuseppa, additional, Madeo, Bruno, additional, Dominici, Massimo, additional, and Sabbatini, Roberto, additional

Published
2023
Full Text
View/download PDF

20. Compassionate Use Program of Ipilimumab and Nivolumab in Intermediate or Poor Risk Metastatic Renal Cell Carcinoma: A Large Multicenter Italian Study

Author

Basso, Umberto, primary, Paolieri, Federico, additional, Rizzo, Mimma, additional, De Giorgi, Ugo, additional, Bracarda, Sergio, additional, Antonuzzo, Lorenzo, additional, Atzori, Francesco, additional, Cartenì, Giacomo, additional, Procopio, Giuseppe, additional, Fratino, Lucia, additional, D’Arcangelo, Manolo, additional, Fornarini, Giuseppe, additional, Zucali, Paolo, additional, Cusmai, Antonio, additional, Santoni, Matteo, additional, Pipitone, Stefania, additional, Carella, Claudia, additional, Panni, Stefano, additional, Deppieri, Filippo, additional, Zagonel, Vittorina, additional, and Tortora, Giampaolo, additional

Published
2022
Full Text
View/download PDF

21. Exceptional response to lurbinectedin and irinotecan in BRCA-mutated platinum-resistant ovarian cancer patient: a case report

Author

Cortesi, Laura, primary, Venturelli, Marta, additional, Barbieri, Elena, additional, Baldessari, Cinzia, additional, Bardasi, Camilla, additional, Coccia, Emanuele, additional, Baglio, Federica, additional, Rimini, Margherita, additional, Greco, Stefano, additional, Napolitano, Martina, additional, Pipitone, Stefania, additional, and Dominici, Massimo, additional

Published
2022
Full Text
View/download PDF

24. Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going

Author

Omarini,Claudia, Guaitoli,Giorgia, Pipitone,Stefania, Moscetti,Luca, Cortesi,Laura, Cascinu,Stefano, and Piacentini,Federico

Subjects
Cancer Management and Research
Abstract

Claudia Omarini,Giorgia Guaitoli,Stefania Pipitone,Luca Moscetti,Laura Cortesi,Stefano Cascinu,Federico Piacentini Department of Medical and Surgical Sciences for Children & Adults, Division of Medical Oncology, University Hospital of Modena, Modena, Italy Abstract: Triple-negative breast cancer (TNBC) remains the poorest-prognosis breast cancer (BC) subtype. Gene expression profiling has identified at least six different triple-negative subtypes with different biology and sensitivity to therapies. The heterogeneous nature of TN tumors may justify the difficulty in treating this BC subtype. Several targeted agents have been investigated in clinical trials without demonstrating a clear survival benefit. Therefore, systemic chemotherapy remains the cornerstone of current clinical practice. Improving the knowledge of tumor biology is mandatory for patient management. In stages II and III, neoadjuvant systemic treatment is an effective option of care. The achievement of a pathological complete response represents an optimal surrogate for survival outcome as well as a test for tumor drug sensitivity. In this review, we provide a brief description of the main predictive biomarkers for tumor response to systemic treatment. Moreover, we review the treatment strategies investigated for TNBCs in neoadjuvant settings focusing on experimental drugs such as immunotherapy and poly [ADP-ribose] polymerase inhibitors that hold promise in the treatment of this aggressive disease. Therefore, the management of TNBC represents an urgent, current, unmet need in daily clinical practice. A key recommendation is to design biology-driven clinical trials wherein TNBC patients may be treated on the basis of tumor molecular profile. Keywords: triple-negative breast cancer, neoadjuvant chemotherapy, BRCA, platinum, immunotherapy, PARP-1 inhibitors

Published
2018

25. Immunotherapy in Dialysis-Dependent Cancer Patients: Our Experience in Patients With Metastatic Renal Cell Carcinoma and a Review of the Literature

Author

Vitale, Maria Giuseppa, primary, Baldessari, Cinzia, additional, Milella, Michele, additional, Buti, Sebastiano, additional, Militello, Anna Maria, additional, Di Girolamo, Stefania, additional, Fornarini, Giuseppe, additional, Perri, Gino, additional, Basso, Umberto, additional, Maruzzo, Marco, additional, Porta, Camillo, additional, Cosmai, Laura, additional, Pipitone, Stefania, additional, Cerma, Krisida, additional, Cascinu, Stefano, additional, and Sabbatini, Roberto, additional

Published
2019
Full Text
View/download PDF

26. Hereditary Pancreatic Cancer: A Retrospective Single-Center Study of 5143 Italian Families with History of BRCA-Related Malignancies

Author

Toss, Angela, primary, Venturelli, Marta, additional, Molinaro, Eleonora, additional, Pipitone, Stefania, additional, Barbieri, Elena, additional, Marchi, Isabella, additional, Tenedini, Elena, additional, Artuso, Lucia, additional, Castellano, Sara, additional, Marino, Marco, additional, Tagliafico, Enrico, additional, Razzaboni, Elisabetta, additional, De Matteis, Elisabetta, additional, Cascinu, Stefano, additional, and Cortesi, Laura, additional

Published
2019
Full Text
View/download PDF

27. Immunotherapy in the treatment of colorectal cancer: a new kid on the block

Author

Spallanzani, Andrea, primary, Gelsomino, Fabio, additional, Caputo, Francesco, additional, Santini, Chiara, additional, Andrikou, Kalliopi, additional, Orsi, Giulia, additional, Rimini, Margherita, additional, Pipitone, Stefania, additional, Riggi, Laura, additional, Bardasi, Camilla, additional, Salati, Massimiliano, additional, and Cascinu, Stefano, additional

Published
2018
Full Text
View/download PDF

30. Hereditary pancreatic cancer: A retrospective single-center study of 5143 Italian families with history of BRCA-related malignancies

Author

Elena Tenedini, Marta Venturelli, Laura Cortesi, Angela Toss, Elena Barbieri, Lucia Artuso, Enrico Tagliafico, Stefania Pipitone, Marco Marino, Isabella Marchi, Elisabetta De Matteis, Stefano Cascinu, Eleonora Molinaro, Elisabetta Razzaboni, Sara Castellano, Toss, Angela, Venturelli, Marta, Molinaro, Eleonora, Pipitone, Stefania, Barbieri, Elena, Marchi, Isabella, Tenedini, Elena, Artuso, Lucia, Castellano, Sara, Marino, Marco, Tagliafico, Enrico, Razzaboni, Elisabetta, De Matteis, Elisabetta, Cascinu, Stefano, and Cortesi, Laura

Subjects
0301 basic medicine, Oncology, medicine.medical_specialty, Cancer Research, animal structures, Genetic testing, endocrine system diseases, pancreatic cancer, BRCA gene, homologous recombination, Single Center, Disease cluster, lcsh:RC254-282, Article, genetic testing, 03 medical and health sciences, 0302 clinical medicine, BRCA genes, Hereditary cancer, Homologous recombination, Pancreatic cancer, Internal medicine, medicine, Family history, skin and connective tissue diseases, Hereditary Pancreatic Cancer, medicine.diagnostic_test, business.industry, medicine.disease, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, female genital diseases and pregnancy complications, 030104 developmental biology, hereditary cancer, 030220 oncology & carcinogenesis, Hereditary Cancer, business, Ovarian cancer
Abstract

The identification of BRCA mutations plays a crucial role in the management of hereditary cancer prevention and treatment. Nonetheless, BRCA-testing in pancreatic cancer (PC) patients is not universally introduced in clinical practice. A retrospective analysis was conducted, firstly, to evaluate the rate of BRCA-positive families among those presenting a family history of PC besides breast and/or ovarian cancer. Secondly, the relationship between BRCA pathogenic variants and PC risk was evaluated. Finally, the characteristics of PC developed in BRCA families were described. Among 5143 family trees reporting breast and/or ovarian cancer cases, 392 showed a family history of PC. A total of 35 families (24.5% selected by the Modena Criteria and 21.3% by the NCCN Criteria) were positive to BRCA testing. Among the BRCA1 mutations, 36.8% were found within a region defined by c.3239&ndash, c.3917, whilst 43.7% of BRCA2 mutations were located within c.7180&ndash, c.8248. This study confirmed that an increase in the rate of positive tests in families with PC when associated to breast and/or ovarian tumors. Moreover, this analysis indicated two possible Pancreatic Cancer Cluster Regions that should be verified in future research. Finally, PC in families with breast and/or ovarian cancer history, particularly in BRCA families, were diagnosed at younger age and showed better one-year overall survival.

Published
2019

31. Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going

Author

Luca Moscetti, Giorgia Guaitoli, Laura Cortesi, Federico Piacentini, Stefano Cascinu, Stefania Pipitone, Claudia Omarini, Omarini, Claudia, Guaitoli, Giorgia, Pipitone, Stefania, Moscetti, Luca, Cortesi, Laura, Cascinu, Stefano, and Piacentini, Federico

Subjects
0301 basic medicine, Drug, Oncology, medicine.medical_specialty, PARP-1 inhibitors, media_common.quotation_subject, medicine.medical_treatment, BRCA, Review, 03 medical and health sciences, 0302 clinical medicine, Breast cancer, Internal medicine, medicine, platinum, Pathological, triple-negative breast cancer [Keywords], Triple-negative breast cancer, media_common, business.industry, Tumor biology, Immunotherapy, medicine.disease, triple-negative breast cancer, neoadjuvant chemotherapy, BRCA, platinum, immunotherapy, PARP-1 inhibitors [Keywords], Gene expression profiling, Clinical trial, 030104 developmental biology, 030220 oncology & carcinogenesis, triple-negative breast cancer, immunotherapy, business, neoadjuvant chemotherapy
Abstract

Triple-negative breast cancer (TNBC) remains the poorest-prognosis breast cancer (BC) subtype. Gene expression profiling has identified at least six different triple-negative subtypes with different biology and sensitivity to therapies. The heterogeneous nature of TN tumors may justify the difficulty in treating this BC subtype. Several targeted agents have been investigated in clinical trials without demonstrating a clear survival benefit. Therefore, systemic chemotherapy remains the cornerstone of current clinical practice. Improving the knowledge of tumor biology is mandatory for patient management. In stages II and III, neoadjuvant systemic treatment is an effective option of care. The achievement of a pathological complete response represents an optimal surrogate for survival outcome as well as a test for tumor drug sensitivity. In this review, we provide a brief description of the main predictive biomarkers for tumor response to systemic treatment. Moreover, we review the treatment strategies investigated for TNBCs in neoadjuvant settings focusing on experimental drugs such as immunotherapy and poly [ADP-ribose] polymerase inhibitors that hold promise in the treatment of this aggressive disease. Therefore, the management of TNBC represents an urgent, current, unmet need in daily clinical practice. A key recommendation is to design biology-driven clinical trials wherein TNBC patients may be treated on the basis of tumor molecular profile.

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results